LL-37 and Influenza: Your Cathelicidin vs the Flu
Antiviral Peptides
Zanamivir-level efficacy
LL-37 reduced influenza disease severity and viral replication in mice to a similar extent as zanamivir (Relenza), a standard antiviral drug, when delivered intranasally.
Barlow et al., PLoS ONE, 2011
Barlow et al., PLoS ONE, 2011
View as imageYour respiratory epithelium does not wait passively for the adaptive immune system to mount an antibody response against influenza. It has its own first-line defense: LL-37, the only human cathelicidin antimicrobial peptide. This 37-amino-acid cationic peptide is produced by airway epithelial cells, neutrophils, and macrophages, and it directly neutralizes influenza A virus before the adaptive immune system even knows an infection has started. As the pillar article on antiviral peptides against influenza covers, multiple peptide classes have anti-influenza activity. LL-37's mechanism is unique among them, and its connection to vitamin D links seasonal flu patterns to peptide biology.
Key Takeaways
- LL-37 inhibits influenza A virus through direct disruption of the viral membrane envelope, a mechanism distinct from surfactant protein D or human defensins[1]
- Intranasal LL-37 reduced influenza disease severity and viral replication in mice to a degree comparable to zanamivir (Relenza)[2]
- LL-37 expression in respiratory epithelium is directly upregulated by active vitamin D metabolites (1,25-dihydroxyvitamin D3), providing a molecular link between vitamin D status and influenza susceptibility[3]
- LL-37 also has antiviral activity against respiratory syncytial virus (RSV), demonstrating broad anti-respiratory-virus capability[4]
- Vitamin D supplementation in asthma patients reduced respiratory infections by 60% over 6 months, potentially through LL-37 induction[5]
- LL-37 increases interferon-beta expression during rhinovirus infection, amplifying the innate antiviral response beyond direct viral killing[6]
How LL-37 Neutralizes Influenza
Tripathi et al. (2013) characterized LL-37's anti-influenza mechanism and found it is fundamentally different from other innate immune molecules that fight flu[1].
Surfactant protein D (SP-D), another lung innate immune molecule, neutralizes influenza by binding to glycans on the viral surface and aggregating viral particles. Human neutrophil defensins (HNPs) inhibit influenza through yet another mechanism. LL-37 does neither. Instead, it disrupts the viral membrane envelope directly.
Influenza is an enveloped virus, meaning its genetic material is surrounded by a lipid bilayer derived from the host cell it budded from. LL-37 is an amphipathic, alpha-helical peptide with a strong positive charge. It inserts into the viral lipid membrane, causing physical disruption. Without an intact envelope, the virus cannot fuse with target cells and cannot initiate infection.
Pre-incubation of influenza virus with LL-37 before adding it to cells produced much stronger inhibition than simultaneous addition. This confirms the mechanism requires direct contact between LL-37 and the virus, with time for membrane disruption to occur. LL-37 showed dose-dependent neutralizing activity against multiple seasonal and mouse-adapted influenza A strains.
The breadth of this mechanism is a strength. Because LL-37 targets the lipid envelope rather than a specific viral protein (like neuraminidase, the target of oseltamivir and zanamivir), it is less vulnerable to resistance mutations. Influenza's rapid antigenic drift and shift render vaccines and some drugs less effective over time, but the lipid envelope is a conserved structural feature that the virus cannot easily modify without losing its ability to infect cells. Any enveloped virus is theoretically susceptible to membrane disruption by LL-37, which explains why the peptide has activity against RSV, herpes simplex virus, and other enveloped pathogens as well.
The concentration dependence is worth noting. Tripathi et al. found that LL-37 concentrations of 10-50 micrograms per milliliter were needed for significant viral inhibition in vitro. Whether airway surface liquid normally contains LL-37 at these concentrations is uncertain. Levels measured in bronchoalveolar lavage fluid from healthy individuals range from 1-5 micrograms per milliliter, suggesting that baseline LL-37 levels may provide partial protection rather than complete viral neutralization. During active infection, neutrophil degranulation can spike local LL-37 concentrations substantially higher.
In Vivo Efficacy: Comparable to Pharmaceutical Antivirals
Barlow et al. (2011) tested LL-37 in a mouse influenza model and produced remarkable results[2]. Mice were infected with influenza A and treated with intranasal LL-37. The peptide:
- Reduced clinical disease severity scores
- Decreased viral titers in lung tissue
- Reduced inflammatory cell infiltration in the airways
- Improved survival
The magnitude of these effects was comparable to zanamivir (Relenza), a standard pharmaceutical neuraminidase inhibitor used clinically to treat influenza. This is a striking result: an endogenous host defense peptide, delivered intranasally, matched the performance of a purpose-built antiviral drug.
LL-37 also modulated the immune response to infection. Beyond directly killing virus, it enhanced recruitment of innate immune cells to the lungs while simultaneously reducing excessive inflammatory damage. This immunomodulatory dual action (enhancing virus clearance while limiting collateral tissue damage) is characteristic of cathelicidins and is one reason LL-37 is studied as both an antimicrobial and immune-regulatory molecule.
LL-37 Against Other Respiratory Viruses
LL-37's antiviral activity is not limited to influenza. Currie et al. (2013) demonstrated that LL-37 has direct antiviral activity against respiratory syncytial virus (RSV), the most common cause of severe respiratory infection in infants[4]. RSV is also an enveloped virus, making it susceptible to the same membrane-disruption mechanism.
Cerps et al. (2025) showed that LL-37 increases interferon-beta expression during rhinovirus infection in nasal epithelial cells[6]. Rhinoviruses are non-enveloped, so LL-37 cannot disrupt their membrane. Instead, it amplifies the innate interferon response, enhancing the cell's own antiviral defense. This means LL-37 has at least two distinct antiviral mechanisms: direct membrane disruption for enveloped viruses and interferon potentiation for non-enveloped viruses.
Bhattacharjya et al. (2024) reviewed the structural basis for LL-37's antimicrobial activities and noted that the alpha-helical structure is essential for both antibacterial and antiviral function[7]. The amphipathic helix allows LL-37 to interact with both lipid membranes (for direct viral and bacterial killing) and cellular receptors (for immunomodulatory effects). This structural versatility is why cathelicidins play such a central role in respiratory defense.
The Vitamin D Connection
LL-37 expression in respiratory epithelial cells is directly regulated by vitamin D. The gene encoding the cathelicidin precursor (hCAP-18/LL-37) contains a vitamin D response element (VDRE) in its promoter region. When the active vitamin D metabolite (1,25-dihydroxyvitamin D3) binds the vitamin D receptor (VDR), it activates transcription of the cathelicidin gene, increasing LL-37 production.
Crane-Godreau et al. (2020) reviewed the evidence linking vitamin D deficiency to suppressed cathelicidin expression and increased respiratory infection susceptibility[3]. They argued that vitamin D deficiency reduces airway LL-37 levels, weakening the first-line antiviral defense against both influenza and SARS-CoV-2.
This molecular pathway provides one of the most compelling biological mechanisms for the well-documented seasonal pattern of influenza. Winter brings reduced UV exposure, lower vitamin D synthesis in skin, decreased circulating vitamin D, reduced respiratory epithelial LL-37 expression, and a more permissive environment for respiratory viral infection. The correlation between winter, low vitamin D, and flu season may be partly mediated through cathelicidin biology.
Ramos-Martinez et al. (2018) tested this connection clinically. Asthma patients supplemented with vitamin D for 6 months experienced a 60% reduction in respiratory infections compared to controls[5]. While the study did not measure LL-37 levels directly, the vitamin D-cathelicidin axis is the most plausible molecular pathway for this effect, given that vitamin D supplementation has been shown to increase circulating LL-37 in other studies. A meta-analysis of vitamin D supplementation trials for respiratory infection prevention (Martineau et al., 2017, BMJ) found a modest protective effect, strongest in individuals who were vitamin D deficient at baseline. This is consistent with the cathelicidin hypothesis: vitamin D supplementation would have the greatest impact on LL-37 levels in people whose starting levels were lowest.
Why LL-37 Is Not Yet an Antiviral Drug
Despite promising preclinical data, LL-37 has not advanced to clinical trials as an antiviral therapeutic for influenza. Several barriers explain this gap:
Stability: LL-37 is a 37-amino-acid linear peptide susceptible to proteolytic degradation. In the lung environment, which contains abundant proteases (especially during infection and inflammation), LL-37 has a short functional half-life. Delivering enough active peptide to the airway surface at therapeutic concentrations requires either frequent dosing or structural modifications to enhance stability.
Cost: Synthesizing a 37-amino-acid peptide at pharmaceutical scale is more expensive than producing small molecule antivirals. The cost-benefit calculation is unfavorable when effective drugs like oseltamivir already exist.
Immune modulation complexity: LL-37 has both anti-inflammatory and pro-inflammatory effects depending on context, concentration, and timing. Its dual immunomodulatory role means that exogenous LL-37 administration could potentially exacerbate inflammatory damage if given at the wrong dose or disease stage. The same peptide that reduces inflammation at one concentration can activate neutrophils and dendritic cells at another.
Vitamin D as a proxy: If increasing LL-37 is the goal, vitamin D supplementation is cheaper, safer, and orally available. Clinical trials of vitamin D for influenza prevention have shown mixed results, but the approach is simpler than direct LL-37 delivery. Ensuring vitamin D sufficiency may be the most practical way to optimize endogenous LL-37 levels in the general population.
Specificity concerns: LL-37 does not distinguish between viral membranes and host cell membranes at high concentrations. Both are lipid bilayers. At therapeutic antiviral concentrations, there is a risk of cytotoxicity to host airway epithelial cells. The therapeutic window between viral killing and host cell damage is narrower than for conventional antivirals that target virus-specific enzymes.
The current research trajectory focuses on LL-37-derived shorter peptide fragments and modified analogs that retain antiviral activity with improved stability, reduced cost, and wider therapeutic windows. Several groups have identified that the central helical region (residues 17-29) retains much of the antimicrobial activity with reduced cytotoxicity. The broader field of antimicrobial peptides for lung defense continues to explore whether engineered cathelicidin variants can overcome these translational barriers.
The defensin family provides a complementary arm of innate antiviral defense in the respiratory tract. While LL-37 disrupts viral membranes through amphipathic helix insertion, defensins use different structural motifs (beta-sheet and disulfide-stabilized structures) to achieve antiviral effects. The two peptide families likely work synergistically in vivo, with their combined activity providing more robust antiviral coverage than either alone.
What LL-37 Tells Us About Innate Antiviral Defense
The LL-37-influenza story illustrates a principle in peptide biology: the body's innate immune system has sophisticated antiviral capabilities that operate before antibodies are produced. LL-37 provides a bridge between exposure and adaptive immunity, limiting viral replication during the critical first 24-72 hours of infection.
For the broader peptide landscape in the sibling article on urumin, amphibian-derived peptides offer another avenue for anti-influenza peptide development. The diversity of natural antiviral peptides across species suggests that evolution has produced multiple independent solutions to the same problem: disrupting enveloped viruses before they can hijack host cells.
The Bottom Line
LL-37, the only human cathelicidin, directly neutralizes influenza A virus by disrupting the viral lipid membrane envelope. In mouse models, intranasal LL-37 reduced disease severity and viral replication to a degree comparable to the pharmaceutical antiviral zanamivir. LL-37 expression in respiratory epithelium is regulated by vitamin D, providing a molecular link between vitamin D status, cathelicidin levels, and influenza susceptibility. LL-37 also has antiviral activity against RSV (through membrane disruption) and rhinovirus (through interferon-beta potentiation). Clinical translation is limited by peptide stability, cost, and the complexity of LL-37's dual immunomodulatory effects.